Biodesix vs Grail
BDSX and GRAL side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BDSX and GRAL compare
Grail is the larger company, worth 53 times as much as Biodesix ($5.6B against $107M).
Biodesix grew revenue faster over the last twelve months (31.2% versus 17.5% for Grail).
Biodesix keeps more of each dollar of sales as profit, with a net margin of −25.7% compared with −244% at Grail.
Grail scores higher on the StockData Score (10 against 4 for Biodesix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BDSX | GRAL |
|---|---|---|
| Size and price | ||
| Market cap | $107M | $5.6B |
| Share price | $10.12 | $125.64 |
| Change, 1 year | 34.2% | 47.6% |
| Change, 5 years | −92.1% | – |
| Beta (5Y) | 0.73 | 2.53 |
| Employees | 334 | 910 |
| StockData Score | ||
| Total score | 4 | 10 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 | 2 |
| Performance score | 1 | 1 |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.0× (better) | 33.7× |
| P/B | 12.3× | 2.3× (better) |
| FCF yield | −17.9% | −5.6% (better) |
| Growth | ||
| Revenue growth (TTM) | 31.2% (better) | 17.5% |
| Revenue growth, 5Y average | 14.2% | – |
| Profitability | ||
| Operating margin | −18.7% (better) | −347% |
| Net margin | −25.7% (better) | −244% |
| FCF margin | −18.1% (better) | −187% |
| Return on equity | −779% | −17.3% (better) |
| Return on invested capital | −55.4% | −27.1% (better) |
| Financial health | ||
| Debt / equity | 5.43 (better) | 0.00 |
| Interest coverage | −2.5× | – |
| Current ratio | 2.96 | 8.93 (better) |
| Altman Z-score | −6.23 | 6.45 (better) |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | −30.7% | – |
| Shareholder yield | −30.7% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 41.4% | 87.6% |
| Held by insiders | – | 11.0% |
| Insider net buying, 12 months | $3.0M (better) | −$38.0M |
| Short interest, % of float | – | 20.1% |
Go deeper
- BDSX stock overview
- BDSX income statement
- BDSX valuation and score
- GRAL stock overview
- GRAL income statement
- GRAL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.